Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Avelumab Merkel cell carcinoma not applicable detail...
TP53 wild-type ALRN-6924 Merkel cell carcinoma sensitive detail...
Unknown unknown Utomilumab Merkel cell carcinoma not applicable detail...
Unknown unknown Pembrolizumab Merkel cell carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02036476 Phase II Cabozantinib Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting
NCT02155647 Phase II Avelumab Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Active, not recruiting
NCT02267603 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Active, not recruiting
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Recruiting
NCT02514824 Phase Ib/II Sapanisertib MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting
NCT02584829 Phase Ib/II IFN-B Avelumab Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Active, not recruiting
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02819843 Phase II Talimogene laherparepvec A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn
NCT02936323 PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting
NCT03071406 Phase II Ipilimumab + Nivolumab Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Recruiting
NCT03074513 Phase II Atezolizumab + Bevacizumab Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting
NCT03271372 Phase III Avelumab Adjuvant Avelumab in Merkel Cell Cancer (ADAM) Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03304639 Phase II Pembrolizumab Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03599713 Phase II INCMGA00012 A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03712605 Phase III Pembrolizumab Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer Recruiting
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Recruiting
NCT03783078 Phase III Pembrolizumab Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913) Recruiting
NCT03787602 Phase II KRT-232 This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1/ PD-L1 Immunotherapy Recruiting
NCT03798639 Phase I Ipilimumab + Nivolumab Nivolumab Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer Recruiting
NCT03853317 Phase II ALT-803 + Avelumab + haNK cells Evaluate Efficacy of Avelumab, haNK and N-803 in Subjects With Progressed MCC on or After Checkpoint Inhibitor Therapy. Not yet recruiting